الصفحة الرئيسية>>Signaling Pathways>> Others>>Antitumor Compound 1

Antitumor Compound 1

رقم الكتالوجGC35363

مركب Antitumor 1 هو مركب قوي يشتمل على imidazopyridine جديد له نشاط مضاد للأورام ممتاز كمكون نشط.

Products are for research use only. Not for human use. We do not sell to patients.

Antitumor Compound 1 التركيب الكيميائي

Cas No.: 420126-30-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
306٫00
متوفر
2mg
216٫00
متوفر
5mg
324٫00
متوفر
10mg
464٫00
متوفر
50mg
1391٫00
متوفر
100mg
1947٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Antitumor Compound 1 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.Reference:Polymer-linked imidazopyridines useful as tumor-targeting cytotoxic agentsBy Kasuya, Hiroshi; Miyazaki, Hideki; Hayakawa, Ichio; Kanno, Yuichi; Watanabe, KazuyoshiFrom Jpn. Kokai Tokkyo Koho (2004), JP 2004002826 A 20040108. Pharmaceuticals containing imidazopyridines for prophylactic and therapeutic treatment of tumorBy Hayakawa, Ichio; Kanno, Yuichi; Azuma, Toshiki; Furukawa, Hidehiko; Naruto, Shunji; Kurakata, ShinichiFrom Jpn. Kokai Tokkyo Koho (2003), JP 2003313126A 20031106.Preparation of imidazopyridine derivatives as antitumor agentsBy Hayakawa, Ichiro; Sugano, Yuichi; Agatsuma, Toshinori; Furukawa, Hidehiko; Kurakata, Shinichi; Naruto, ShunjiFrom PCT Int. Appl. (2002), WO 2002034748 A1 20020502.

مراجعات

Review for Antitumor Compound 1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Antitumor Compound 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.